Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death-Reference-Cited by-同舟云学术

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death

Published:2015-10-30 Issue:1 Volume:29 Page:34-42
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Ho Thai H^ORCID,Kapur Payal,Joseph Richard W,Serie Daniel J,Eckel-Passow Jeanette E,Tong Pan,Wang Jing,Castle Erik P,Stanton Melissa L,Cheville John C,Jonasch Eric,Brugarolas James,Parker Alexander S

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/modpathol2015123.pdf

Reference24 articles.

1. Creighton CJ, Morgan M, Gunaratne PH et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43–49.

2. Kudithipudi S, Jeltsch A . Role of somatic cancer mutations in human protein lysine methyltransferases. Biochim Biophys Acta 2014;1846:366–379.

3. Hu M, Sun XJ, Zhang YL et al. Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling. Proc Natl Acad Sci USA 2010;107:2956–2961.

4. Mar BG, Bullinger LB, McLean KM et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 2014;5:3469–3475.

5. Fontebasso AM, Schwartzentruber J, Khuong-Quang DA et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol 2013;125:659–669.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clear Cell Renal Cell Carcinoma: A Comprehensive Review of its Histopathology, Genetics, and Differential Diagnosis;International Journal of Surgical Pathology;2024-07-25

2. Understanding Factors that Influence Prognosis and Response to Therapy in Clear Cell Renal Cell Carcinoma;Advances in Anatomic Pathology;2024-01-05

3. SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer;Cancer Research;2023-09-11

4. Loss of SETD2‐mediated downregulation of intracellular and exosomal miRNA‐10b determines MAPK pathway activation and multidrug resistance in renal cancer;Molecular Carcinogenesis;2023-08-17

5. A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation;BMC Cancer;2023-08-01